pyrazines has been researched along with u 62840 in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (95.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Clozel, M; Ernst, R; Hess, P; Morrison, K; Studer, R | 1 |
| Clozel, M; Ernst, R; Haag, F; Kauser, K; Morrison, K; Studer, R | 1 |
| Kovacs, G; Olschewski, H | 1 |
| Morrell, N; Sitbon, O | 1 |
| Benyahia, C; Boukais, K; Clapp, L; Danel, C; Fabre, A; Gomez, I; Leséche, G; Longrois, D; Norel, X; Silverstein, A | 1 |
| Clapp, LH; Ledwozyw, A; Orie, NN; Whittle, BJ; Williams, DJ | 1 |
| Del Pozo, R; Escribano-Subias, P; Hernandez Gonzalez, I | 1 |
| Clozel, M; Gatfield, J; Gnerre, C; Hess, P; Iglarz, M; Menyhart, K; Monnier, L; Morrison, K; Nayler, O; Wanner, D | 1 |
| Bates, RE; Frantz, RP; Thurber, KM; Williams, BM | 1 |
| Alejos, J; Drogalis-Kim, DE; Gallotti, R; Satou, G | 1 |
| Dutt, M; Feldman, J; Habib, N; Radosevich, J | 1 |
| El Yafawi, R; Wirth, JA | 1 |
| Furukawa, A; Goto, M; Iwahori, H; Kawamura, A; Ohashi, N; Okabe, T; Tamura, Y | 1 |
| Akerström, F; Berenguel Senén, A; Escribano Subías, P; Lázaro Salvador, M; Martinez Mateo, V; Rodriguez Padial, L | 1 |
| Fanous, SM; Janmohamed, M | 1 |
| Benza, RL; Chin, KM; Eggert, M; Farber, HW; Fisher, M; Fortin, TA; Fritz, JS; Frost, A; Janmohamed, M; Kim, NH; McConnell, JW; McEvoy, C; McLaughlin, V; Miller, CE; Pfister, T; Poch, D; Shiraga, Y | 1 |
| Airhart, S; Badie, N; Benza, R; Raina, A; Verlinden, N | 1 |
| Escribano Subías, P; Lázaro Salvador, M; Rodriguez Padial, L | 1 |
| Bock, MJ; Koo, R; Lo, J | 1 |
| DeChristopher, A; Fann, J; Feldman, J; Irandost, M; Radosevich, JJ | 1 |
4 review(s) available for pyrazines and u 62840
| Article | Year |
|---|---|
Pathways in pulmonary arterial hypertension: the future is here.
Topics: Acetamides; Animals; Antihypertensive Agents; Benzamides; Clinical Trials as Topic; Drugs, Investigational; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Epoprostenol; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Lisuride; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Serotonin Antagonists; Sulfonamides | 2012 |
The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines; Receptors, Epoprostenol | 2017 |
Oral treprostinil in the treatment of pulmonary arterial hypertension.
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Clinical Trials as Topic; Drug Approval; Epoprostenol; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Pyrazines; Receptors, Prostaglandin; Treatment Outcome | 2017 |
What Is the Role of Oral Prostacyclin Pathway Medications in Pulmonary Arterial Hypertension Management?
Topics: Acetamides; Antihypertensive Agents; Epoprostenol; Humans; Hypertension, Pulmonary; Pyrazines | 2017 |
1 trial(s) available for pyrazines and u 62840
| Article | Year |
|---|---|
Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Topics: Acetamides; Administration, Inhalation; Administration, Oral; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Substitution; Drug Tolerance; Epoprostenol; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prodrugs; Prospective Studies; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Treatment Outcome | 2019 |
15 other study(ies) available for pyrazines and u 62840
| Article | Year |
|---|---|
Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
Topics: Acetamides; Animals; Dinoprostone; Dose-Response Relationship, Drug; Epoprostenol; Gastric Emptying; Gastrointestinal Transit; Humans; Iloprost; Male; Muscle Contraction; Pulmonary Artery; Pyrazines; Rats; Receptors, Epoprostenol; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach | 2010 |
Differential effects of Selexipag [corrected] and prostacyclin analogs in rat pulmonary artery.
Topics: Acetamides; Acetates; Alprostadil; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Epoprostenol; Hypertension, Pulmonary; In Vitro Techniques; Male; Pulmonary Artery; Pyrazines; Rats; Rats, Wistar; Receptors, Epoprostenol; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2012 |
[Pulmonary hypertension].
Topics: Acetamides; Administration, Oral; Antihypertensive Agents; Benzamides; Drug Therapy, Combination; Early Medical Intervention; Epoprostenol; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Pyrazines; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sulfonamides | 2012 |
A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
Topics: Acetates; Aged; Drug Evaluation, Preclinical; Epoprostenol; Female; Humans; Iloprost; In Vitro Techniques; Inhibitory Concentration 50; Male; Middle Aged; Molecular Mimicry; Pulmonary Artery; Pulmonary Veins; Pyrazines; Receptors, Epoprostenol; Receptors, Immunologic; Receptors, Prostaglandin; Receptors, Prostaglandin E, EP4 Subtype; Vasodilation; Vasodilator Agents | 2013 |
Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Topics: Acetamides; Acetates; Animals; Benzofurans; Benzyl Compounds; Epoprostenol; Female; Iloprost; Imidazoles; Male; Propionates; Pulmonary Artery; Pulmonary Veins; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation | 2013 |
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Topics: Acetamides; Acetates; Animals; beta-Arrestins; Cell Proliferation; CHO Cells; Contractile Proteins; Cricetinae; Cricetulus; Cyclic AMP; Epoprostenol; Extracellular Matrix; Humans; Hypertension, Pulmonary; Iloprost; Male; Muscle Contraction; Muscle Relaxation; Pyrazines; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Epoprostenol | 2017 |
Transition of Intravenous Treprostinil to Oral Therapy in a Patient with Functional Class IV Chronic Thromboembolic Pulmonary Hypertension.
Topics: Acetamides; Administration, Oral; Adult; Antihypertensive Agents; Chronic Disease; Epoprostenol; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Paraplegia; Pyrazines; Severity of Illness Index; Ventricular Dysfunction, Right | 2017 |
Single-Center Experience Using Selexipag in a Pediatric Population.
Topics: Acetamides; Adolescent; Antihypertensive Agents; Child; Epoprostenol; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pyrazines; Treatment Outcome; Walk Test; Young Adult | 2017 |
Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension.
Topics: Acetamides; Adult; Antihypertensive Agents; Drug Therapy, Combination; Epoprostenol; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Humans; Prospective Studies; Pyrazines; Pyrimidines; Sulfonamides | 2017 |
Living With Severe Pulmonary Arterial Hypertension Without an Infusion Pump? Selexipag has a Role to Play.
Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Drug Therapy, Combination; Epoprostenol; Female; Humans; Infusion Pumps; Middle Aged; Phenylpropionates; Pulmonary Arterial Hypertension; Pyrazines; Pyridazines; Sildenafil Citrate; Tadalafil; Vasodilator Agents | 2019 |
Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Drug Substitution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Male; Middle Aged; Pyrazines | 2018 |
Use of an implantable wireless pulmonary pressure monitor during transition of therapy in pulmonary arterial hypertension.
Topics: Acetamides; Antihypertensive Agents; Drug Substitution; Epoprostenol; Equipment Design; Female; Humans; Middle Aged; Monitoring, Physiologic; Prodrugs; Pulmonary Arterial Hypertension; Pulmonary Artery; Pulmonary Wedge Pressure; Pyrazines; Remote Sensing Technology | 2019 |
Right Heart Catheterization Further Confirms Successful Transition from Parenteral Prostanoid to Oral Selexipag.
Topics: Acetamides; Administration, Oral; Cardiac Catheterization; Drug Substitution; Epoprostenol; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Pyrazines | 2019 |
Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Echocardiography; Enteral Nutrition; Epoprostenol; Humans; Infant, Newborn; Infusions, Intravenous; Male; Pulmonary Arterial Hypertension; Pulmonary Wedge Pressure; Pyrazines; Receptors, Prostaglandin | 2019 |
Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension.
Topics: Acetamides; Administration, Intravenous; Administration, Oral; Aged; Antihypertensive Agents; Blood Pressure; Drug Substitution; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Injections, Subcutaneous; Pyrazines; Time Factors | 2020 |